vs
Side-by-side financial comparison of GENCOR INDUSTRIES INC (GENC) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
GENCOR INDUSTRIES INC is the larger business by last-quarter revenue ($23.6M vs $20.4M, roughly 1.2× Sight Sciences, Inc.). GENCOR INDUSTRIES INC runs the higher net margin — 14.6% vs -20.4%, a 35.0% gap on every dollar of revenue. On growth, Sight Sciences, Inc. posted the faster year-over-year revenue change (6.9% vs -25.0%). GENCOR INDUSTRIES INC produced more free cash flow last quarter ($10.1M vs $-2.0M). Over the past eight quarters, Sight Sciences, Inc.'s revenue compounded faster (2.9% CAGR vs -23.9%).
Gencor Industries Inc is a leading manufacturer of heavy construction and infrastructure equipment, specializing in asphalt production plants, thermal combustion systems, and supporting road-building machinery. It primarily serves North American and global construction markets, supplying products to both public sector infrastructure projects and private commercial construction operators.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
GENC vs SGHT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.6M | $20.4M |
| Net Profit | $3.4M | $-4.2M |
| Gross Margin | 28.7% | 87.3% |
| Operating Margin | 13.2% | -18.0% |
| Net Margin | 14.6% | -20.4% |
| Revenue YoY | -25.0% | 6.9% |
| Net Profit YoY | -9.8% | 64.9% |
| EPS (diluted) | $0.23 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.6M | $20.4M | ||
| Q3 25 | $18.8M | $19.9M | ||
| Q2 25 | $27.0M | $19.6M | ||
| Q1 25 | $38.2M | $17.5M | ||
| Q4 24 | $31.4M | $19.1M | ||
| Q3 24 | $20.9M | $20.2M | ||
| Q2 24 | $25.6M | $21.4M | ||
| Q1 24 | $40.7M | $19.3M |
| Q4 25 | $3.4M | $-4.2M | ||
| Q3 25 | $1.9M | $-8.2M | ||
| Q2 25 | $3.8M | $-11.9M | ||
| Q1 25 | $6.1M | $-14.2M | ||
| Q4 24 | $3.8M | $-11.8M | ||
| Q3 24 | $1.5M | $-11.1M | ||
| Q2 24 | $2.6M | $-12.3M | ||
| Q1 24 | $6.2M | $-16.3M |
| Q4 25 | 28.7% | 87.3% | ||
| Q3 25 | 24.2% | 86.4% | ||
| Q2 25 | 26.5% | 84.8% | ||
| Q1 25 | 29.7% | 86.2% | ||
| Q4 24 | 27.6% | 86.8% | ||
| Q3 24 | 25.6% | 83.9% | ||
| Q2 24 | 23.9% | 85.8% | ||
| Q1 24 | 30.3% | 85.5% |
| Q4 25 | 13.2% | -18.0% | ||
| Q3 25 | -1.2% | -39.7% | ||
| Q2 25 | 11.6% | -59.6% | ||
| Q1 25 | 17.0% | -79.2% | ||
| Q4 24 | 14.7% | -62.5% | ||
| Q3 24 | 5.9% | -55.7% | ||
| Q2 24 | 7.8% | -59.2% | ||
| Q1 24 | 17.4% | -76.4% |
| Q4 25 | 14.6% | -20.4% | ||
| Q3 25 | 10.2% | -41.0% | ||
| Q2 25 | 14.2% | -61.0% | ||
| Q1 25 | 16.0% | -80.8% | ||
| Q4 24 | 12.1% | -62.1% | ||
| Q3 24 | 6.9% | -54.9% | ||
| Q2 24 | 10.0% | -57.7% | ||
| Q1 24 | 15.3% | -84.4% |
| Q4 25 | $0.23 | $-0.07 | ||
| Q3 25 | $0.13 | $-0.16 | ||
| Q2 25 | $0.26 | $-0.23 | ||
| Q1 25 | $0.42 | $-0.28 | ||
| Q4 24 | $0.26 | $-0.23 | ||
| Q3 24 | $0.10 | $-0.22 | ||
| Q2 24 | $0.17 | $-0.25 | ||
| Q1 24 | $0.42 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $147.7M | $92.0M |
| Total DebtLower is stronger | — | $42.4M |
| Stockholders' EquityBook value | $215.2M | $63.9M |
| Total Assets | $228.9M | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $147.7M | $92.0M | ||
| Q3 25 | $136.3M | $92.4M | ||
| Q2 25 | $136.0M | $101.5M | ||
| Q1 25 | $143.7M | $108.8M | ||
| Q4 24 | $130.1M | $120.4M | ||
| Q3 24 | $115.4M | $118.6M | ||
| Q2 24 | $116.6M | $118.2M | ||
| Q1 24 | $117.1M | $127.3M |
| Q4 25 | — | $42.4M | ||
| Q3 25 | $0 | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | $0 | $37.1M | ||
| Q2 24 | — | $35.0M | ||
| Q1 24 | — | $35.0M |
| Q4 25 | $215.2M | $63.9M | ||
| Q3 25 | $211.8M | $64.3M | ||
| Q2 25 | $209.9M | $70.0M | ||
| Q1 25 | $206.1M | $77.6M | ||
| Q4 24 | $200.0M | $87.5M | ||
| Q3 24 | $196.1M | $95.0M | ||
| Q2 24 | $194.7M | $101.6M | ||
| Q1 24 | $192.1M | $109.2M |
| Q4 25 | $228.9M | $115.3M | ||
| Q3 25 | $222.6M | $116.3M | ||
| Q2 25 | $220.2M | $122.0M | ||
| Q1 25 | $223.9M | $129.7M | ||
| Q4 24 | $218.2M | $142.8M | ||
| Q3 24 | $208.1M | $143.6M | ||
| Q2 24 | $201.8M | $149.7M | ||
| Q1 24 | $206.0M | $155.6M |
| Q4 25 | — | 0.66× | ||
| Q3 25 | 0.00× | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | 0.00× | 0.39× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.1M | $-1.8M |
| Free Cash FlowOCF − Capex | $10.1M | $-2.0M |
| FCF MarginFCF / Revenue | 43.0% | -9.7% |
| Capex IntensityCapex / Revenue | 4.1% | 0.8% |
| Cash ConversionOCF / Net Profit | 3.23× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-3.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.1M | $-1.8M | ||
| Q3 25 | $-275.0K | $-8.7M | ||
| Q2 25 | $-23.9M | $-7.5M | ||
| Q1 25 | $12.4M | $-11.6M | ||
| Q4 24 | $14.8M | $-3.5M | ||
| Q3 24 | $-3.2M | $362.0K | ||
| Q2 24 | $-1.0M | $-9.5M | ||
| Q1 24 | $11.7M | $-9.8M |
| Q4 25 | $10.1M | $-2.0M | ||
| Q3 25 | $-1.3M | $-8.9M | ||
| Q2 25 | $-24.4M | $-7.8M | ||
| Q1 25 | $12.3M | — | ||
| Q4 24 | $14.5M | $-3.6M | ||
| Q3 24 | $-3.3M | $311.0K | ||
| Q2 24 | $-1.4M | $-9.5M | ||
| Q1 24 | $11.7M | $-9.9M |
| Q4 25 | 43.0% | -9.7% | ||
| Q3 25 | -6.8% | -44.7% | ||
| Q2 25 | -90.4% | -39.6% | ||
| Q1 25 | 32.2% | — | ||
| Q4 24 | 46.1% | -18.9% | ||
| Q3 24 | -15.8% | 1.5% | ||
| Q2 24 | -5.6% | -44.7% | ||
| Q1 24 | 28.7% | -51.4% |
| Q4 25 | 4.1% | 0.8% | ||
| Q3 25 | 5.4% | 0.9% | ||
| Q2 25 | 1.8% | 1.1% | ||
| Q1 25 | 0.4% | 0.0% | ||
| Q4 24 | 1.0% | 0.7% | ||
| Q3 24 | 0.4% | 0.3% | ||
| Q2 24 | 1.5% | 0.4% | ||
| Q1 24 | 0.0% | 0.6% |
| Q4 25 | 3.23× | — | ||
| Q3 25 | -0.14× | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | 2.04× | — | ||
| Q4 24 | 3.88× | — | ||
| Q3 24 | -2.22× | — | ||
| Q2 24 | -0.41× | — | ||
| Q1 24 | 1.87× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GENC
Segment breakdown not available.
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
